- Novo Nordisk’s Earnings Come After a Dramatic Guidance Cut. What to Look for Now. Barron’s
- Wegovy maker Novo Nordisk’s sales hike in second quarter CNBC
- Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock? Yahoo Finance
- Ozempic Maker’s Plight Shows Managing Markets Counts Too Bloomberg.com
- Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay MarketWatch
Source link
